Daniel Wilhelm Olivier

Dr. Daniel Wilhelm Olivier

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Experimental Cell Research
Verified
Journal Article
Closed access
DODaniel Wilhelm Olivier
Daniel Wilhelm Olivier
EPEtheresia Pretorius
Etheresia Pretorius
Anna-Mart EngelbrechtAnna-Mart Engelbrecht
Anna-Mart Engelbrecht

23 August 2024 in Biology
Verified
Journal Article
Open access
PDF file
DODaniel Wilhelm Olivier
Daniel Wilhelm Olivier
CECarla Eksteen
Carla Eksteen
MPManisha du Plessis
Manisha du Plessis
LJLouis De Jager
Louis De Jager
LELize Engelbrecht
Lize Engelbrecht
Anna-Mart EngelbrechtAnna-Mart Engelbrecht
Anna-Mart Engelbrecht
Background: Previous research has shown that the Serum Amyloid A (SAA) protein family is intricately involved in inflammatory signaling and various disease pathologies. We have previously demonstrated that SAA is associated with increased colitis disease severity and the promotion of tumorigenesis. However, the specific role of SAA proteins in breast cancer pathology remains unclear. Therefore, we investigated the role of systemic SAA1 and SAA2 (SAA1/2) in a triple-negative breast cancer mouse model. Methods: Syngeneic breast tumors were established in wild-type mice, and mice lacking the SAA1/2 (SAADKO). Subsequently, tumor volume was monitored, species survival determined, the inflammatory profiles of mice assessed with a multiplex assay, and tumor molecular biology and histology characterized with Western blotting and H&E histological staining. Results: WT tumor-bearing mice had increased levels of plasma SAA compared to wild-type control mice, while SAADKO control and tumor-bearing mice presented with lower levels of SAA in their plasma. SAADKO tumor-bearing mice also displayed significantly lower concentrations of systemic inflammatory markers. Tumors from SAADKO mice overall had lower levels of SAA compared to tumors from wild-type mice, decreased apoptosis and inflammasome signaling, and little to no tumor necrosis. Conclusions: We demonstrated that systemic SAA1/2 stimulates the activation of the NLRP3 inflammasome in breast tumors, leading to the production of pro-inflammatory cytokines. This, in turn, promoted apoptosis and tumor necrosis but did not significantly impact tumor growth or histological grading.

13 December 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
DMDeanne Nixie R. Miao
Deanne Nixie R. Miao
FLFeryal Ladha
Feryal Ladha
SLSarah M. Lyle
Sarah M. Lyle
DODaniel Wilhelm Olivier
Daniel Wilhelm Olivier
SASamah Ahmed
Samah Ahmed
BDBritt Drogemoller
Britt Drogemoller


14 December 2022 in Research Square
Verified
Preprint
Open access
PDF file
DODaniel Wilhelm Olivier
Daniel Wilhelm Olivier
CFCarla Fourie
Carla Fourie
MPManisha du Plessis
Manisha du Plessis
LJLouis Johann de Jager
Louis Johann de Jager
LELize Engelbrecht
Lize Engelbrecht
AEAnna-Mart Engelbrecht
Anna-Mart Engelbrecht
Background Past research has identified the family of Serum Amyloid A (SAA) proteins to be intricately involved in inflammatory signaling and various disease pathologies. In cancer patients, SAA proteins have been reported to be upregulated in blood and tumor tissue, correlating in many instances with disease progression. However, the exact role of SAA proteins in cancer pathology remains to be fully elucidated. We, therefore, investigated systemic SAA1 and SAA2 (SAA1/2) in modulating the inflammasome, cell cycle, apoptosis, and epithelial-to-mesenchymal transition (EMT). Methods Breast cancer allografts were established in wild-type mice (WT), and mice lacking the SAA1/2 orthologs (SAADKO). Subsequently, tumor volume was monitored, species survival determined, the inflammatory profiles of mice assessed with a multiplex assay, and tumor molecular biology and histology characterized with western blotting and H&E histological staining. Results WT tumor-bearing mice had increased levels of plasma SAA compared to WT control mice, while SAADKO control and tumor-bearing mice presented with lower levels of SAA in their plasma. SAADKO tumor-bearing mice also displayed significantly lower concentrations of the systemic inflammatory markers, IL-1β, IL-6, and IL-10 compared to WT tumor-bearing mice. Tumors from SAADKO mice overall had lower levels of SAA compared to tumors from WT mice, decreased apoptotic (cytochrome c, caspases 9/3, PARP), and inflammasome (NFκB, caspase 1, NLRP3) signaling, with little to no tumor necrosis. Conclusions We show that systemic SAA1/2 promotes the activation of the NLRP3 inflammasome in breast cancer tumors and the generation of pro-inflammatory cytokines, which promotes apoptosis and tumor necrosis. Based on these findings, we hypothesize that SAA1/2-mediated necrosis is due to NLRP3-mediated pore formation in membranes, while apoptosis signaling is likely mediated via the TIF-IA-NF-κB-apoptosis axis.